Study guide

5.5 Legitimate Medical Purpose, Corresponding Responsibility & Red Flags

Oregon Multistate Pharmacy Jurisprudence Examination MPJE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Oregon Legal Framework

1.1 Oregon MPJE Format, Fees, Blueprint & 2027 Changes 1.2 Federal–Oregon Legal Hierarchy, Agencies & the Board of Pharmacy

2 Chapter 2: Pharmacist & Pharmacist-in-Charge Responsibilities

2.1 Pharmacist Responsibilities, Supervision & Prohibited Practices 2.2 Pharmacist-in-Charge: Qualifications, Duties, Inventories & Self-Inspection

3 Chapter 3: Pharmacy Technicians, Interns & Preceptors

3.1 Pharmacy Technicians (COPT & PT): Licensure, Permitted Tasks & Limits 3.2 Pharmacy Interns & Preceptors: Licensure, Scope & Supervision

4 Chapter 4: Licensure, Renewal, Discipline & Impaired Practitioners

4.1 Pharmacist Licensure by Examination, Score Transfer & Reciprocity 4.2 License Renewal, Continuing Pharmacy Education & Lapse Rules 4.3 Grounds for Discipline, Sanctions & Mandatory Reporting Deadlines 4.4 Impaired Practitioners & the Health Professionals' Services Program (HPSP)

5 Chapter 5: Prescriber Authority & Prescription Requirements

5.1 Prescriber Authority, DEA Registration & Out-of-State Prescriptions 5.2 Non-Controlled Prescriptions: Required Elements, Signatures, Expiration & Refills 5.3 Controlled Substance Prescriptions: Schedules II–V, EPCS, Emergency Orders & Oregon's CV Limit 5.4 Drug-Use Limitations & Special Prescriptions: REMS, Death with Dignity, EPT & Standing Orders 5.5 Legitimate Medical Purpose, Corresponding Responsibility & Red Flags

6 Chapter 6: Pharmacist Clinical Services & Prescriptive Authority

6.1 CDTM, Clinical Pharmacy Agreements, MTM & Laboratory Testing 6.2 Pharmacist Prescribing: Statewide Protocols, the Formulary & General Requirements 6.3 Pharmacist Prescribing of Hormonal Contraception (ORS 689.689) 6.4 Tobacco Cessation Protocol: Training, Screening, NRT & Non-NRT Prescribing 6.5 Vaccine Prescribing & Administration: Age Floors, Protocols, Training & ALERT IIS 6.6 Opioid Overdose Reversal & MOUD: Naloxone Prescribing, Standing Orders, Immunity & Buprenorphine

7 Chapter 7: Counseling, Language Access & Confidentiality

7.1 Patient Counseling: Triggers, Who May Offer or Accept a Refusal & Documentation 7.2 Language Access & Accessibility: Dual-Language Labels, Registry Interpreters & Prescription Readers 7.3 Patient Confidentiality: Oregon Rules, HIPAA, Part 2 & PDMP Privacy

8 Chapter 8: The Dispensing Process

8.1 Prospective Drug Utilization Review: Oregon's Eight Categories, Documentation & Who May Perform It 8.2 Oregon PDMP: Reporting Within 72 Hours, Covered Drugs, Access & Confidentiality 8.3 Prescription Transfers: Oregon's Next-Business-Day Duty & Federal Controlled Substance Limits 8.4 Dispensing Exceptions: 72-Hour Emergency Refills, Continuation of Therapy, Insulin & Declared Emergencies 8.5 Partial Fills: Schedule II (72-Hour, 30-Day CARA & 60-Day LTCF/Terminal) and Schedules III–V 8.6 Prescription Labeling: Oregon Elements, Physical Description, Expiration Dating & Med Paks 8.7 Packaging: PPPA Child-Resistant Containers, Waivers, Exemptions & Oregon's New-Container Rule 8.8 Conditions Prohibiting Dispensing, Quarantine, Returned Drugs & Charitable Reuse

9 Chapter 9: Nonprescription & Restricted Products

9.1 Nonprescription Drugs: Outlet Registration, Drug Facts Labeling & OTC Packaging 9.2 Dispensing-Restricted Nonprescription Products: Pseudoephedrine, Exempt Schedule V & Others

10 Chapter 10: Product Selection: Generic & Biologic Substitution

10.1 Product Selection: Generic Substitution (ORS 689.515) & Biologic Interchange (ORS 689.522)

11 Chapter 11: Acquisition, Records, Inventories & Loss Reporting

11.1 Ordering & Acquiring Controlled Substances: DEA Registration, Form 222, CSOS & the 5% Rule 11.2 Distribution Records, DSCSA, Recalls & Oregon Record Retention 11.3 Controlled Substance Inventories: Oregon's 367-Day, 93-Day, 31-Day & 15-Day Rules 11.4 Theft & Loss Reporting, Disposal, Reverse Distribution & Take-Back Receptacles

12 Chapter 12: Pharmacy Operations, Storage, Security & Special Practice Settings

12.1 Pharmacy Operations: Pharmacist Presence, Policies, Equipment, Signage, Hours & Closures 12.2 Drug Storage & Cold Chain: Temperatures, Monitoring Plans, Excursions & Vaccine Units 12.3 Security & Non-Pharmacist Access: Keys, Double Set-Ups, Institutional Night Access & DEA Controls 12.4 Hazardous Drugs: NIOSH 2024 List, USP 800 Controls, Assessment of Risk & Disposal 12.5 Compounding: OAR 855-183 (June 2026), USP 795/797/800, 503A vs. 503B & Beyond-Use Dates 12.6 Delivery of Drugs: Depots, Mail Delivery, Prescription Lockers, Kiosks & Mobile Pharmacies 12.7 Central Fill, Remote Processing, Telework & Remote Dispensing Site Pharmacies

13 Chapter 13: Drug Outlet Registration, Inspection & Institutional Practice

13.1 Drug Outlet Classes, Registration, Changes of Ownership/Location/Name & Non-Resident Pharmacies 13.2 Inspections, Self-Inspection Forms & Discipline of Drug Outlets 13.3 Institutional & Long-Term Care Practice: Drug Rooms, Night Access, E-Kits, ADCs & ED Prepacks

5.5 Legitimate Medical Purpose, Corresponding Responsibility & Red Flags

Key Takeaways Explain This Topic AI

Under 21 CFR 1306.04, an Oregon pharmacist shares corresponding responsibility for every controlled substance prescription, and willful blindness to red flags is not a defense.

OAR 855-115-0130 requires that every prescription, controlled or not, be dispensed under a valid patient–practitioner relationship and for a legitimate medical purpose.

A prescriber's office confirming that a prescription was written establishes authenticity, not legitimacy, so unresolved red flags still justify refusal.

Oregon does not require a PDMP query before every fill, but a pharmacist may not refuse a valid prescription solely because the PDMP is unavailable (ORS 431A.870).

OHA standing orders, expedited partner therapy, compliant telemedicine and pharmacist protocols are recognized exceptions to a traditional individual relationship.

Last updated: October 2026

Why this matters

Area 3.1 tests "responsibilities for determining whether prescriptions ... are issued for a legitimate medical purpose." Federal law places a corresponding responsibility on the pharmacist (21 CFR 1306.04(a)). Oregon writes the same duty into its rules. Every pharmacist must ensure that prescriptions are dispensed under a valid prescription , a valid patient–practitioner relationship and for a legitimate medical purpose (OAR 855-115-0130(1)(e); OAR 855-041-1105(1)). For controlled substances, ORS 475.185(4)–(5) adds that they may be dispensed only for a medical purpose and only in good faith in the course of professional practice.

The doctrine

Under 21 CFR 1306.04(a), a controlled substance prescription is valid only if it is issued for a legitimate medical purpose by an individual practitioner acting in the usual course of professional practice . The prescriber bears primary responsibility, but a corresponding responsibility rests with the pharmacist who fills it . A pharmacist who knowingly fills a prescription that is not legitimate, or who deliberately ignores obvious signs that it is not, is treated as having distributed a controlled substance unlawfully. Willful blindness is not a defense.

A prescriber's confirmation that they "wrote it" does not settle the question when the red flags concern legitimacy rather than authenticity.

Common red flags

Category Examples

Drug combination Opioid plus benzodiazepine plus muscle relaxant (often carisoprodol), or high-dose immediate-release opioids for a new patient

Patient pattern Early refill requests, multiple prescribers or pharmacies on the PDMP, "lost" or "stolen" medication claims, insistence on brand or specific manufacturers

Geography Long travel distances to prescriber or pharmacy with no explanation; many patients from the same distant clinic

Prescriber pattern Identical drugs, strengths and quantities for many unrelated patients; prescribing far outside specialty

  • Payment Cash for expensive controlled substances despite insurance
  • Document Altered quantities, mismatched handwriting, wrong DEA format, photocopies
  • Resolving red flags

The pharmacist's options, in order:

Investigate. Talk with the patient, review the dispensing history, and query the Oregon PDMP . Oregon law doesn't require a PDMP query before every fill (ORS 431A.865(8)), but the PDMP is the most practical tool for resolving red flags. It also helps document professional judgment.

Contact the prescriber to discuss the clinical rationale: diagnosis, treatment plan, prior therapy and any concerns the PDMP raises.

Document what was found and decided. DUR documentation is required whenever a concern is identified (OAR 855-115-0140(2)).

Refuse to dispense if the concerns cannot be resolved. A pharmacist may not refuse a valid prescription solely because PDMP information is temporarily unavailable (ORS 431A.870). That is different from refusing because unresolved red flags exist.

Note

Corresponding responsibility applies to every prescription in the Oregon rules, not only controlled substances. OAR 855-115-0130 requires a valid patient–practitioner relationship and a legitimate medical purpose for all dispensing. The DEA enforcement focus, however, is on controlled substances.

Valid patient–practitioner relationship

A prescription issued without a real clinical relationship is not valid. Examples include an online questionnaire alone, or a prescriber "rubber-stamping" orders from a website. Examples of legitimate exceptions:

OHA standing orders , which by rule need no individual relationship (OAR 855-041-1105(7)).

Expedited partner therapy (ORS 676.350).

Telemedicine that meets federal and state standards, including DEA's temporary flexibilities through December 31, 2026.

Pharmacist protocol prescribing , where the pharmacist's own assessment is the clinical encounter.

Prescriptions for self or family

Oregon's pharmacy rules don't address physicians prescribing for themselves or family members. That is a matter for the prescriber's board. A pharmacist reviews such orders like any other, for legitimacy, and is especially alert when controlled substances are involved. Pharmacists themselves may not prescribe for themselves under the Board's formulary or protocols (OAR 855-115-0335).

Documenting and escalating

Document the review. Record the red flags, the PDMP findings, the prescriber conversation and the decision. That documentation shows professional judgment if the Board or DEA later asks.

Escalate prescriber concerns properly. If the pattern suggests a prescriber is practicing unprofessionally, ORS 676.150 requires a report to that prescriber's board within 10 working days. Diversion suspected inside the pharmacy follows the 1-business-day theft and loss rules.

Forged or altered prescriptions. A pharmacist who identifies a forgery may decline it and contact the prescriber. HIPAA permits limited disclosure to law enforcement about crimes committed on the premises (45 CFR 164.512(f)(5)).

Exam scenario

A new patient presents prescriptions for oxycodone 30 mg #180, alprazolam 2 mg #90 and carisoprodol 350 mg #90 from a prescriber 200 miles away, and wants to pay cash. The pharmacist queries the PDMP and finds fills at four pharmacies in the last 60 days. The pharmacist calls the clinic, and a receptionist confirms "the doctor wrote these." That confirms authenticity, not legitimacy. Unless the prescriber provides a credible clinical explanation that resolves the red flags, the pharmacist should decline to fill , document the PDMP findings and conversations, and consider whether a report is warranted. Under ORS 676.150, a report goes to the prescriber's board if there is reasonable cause to believe the prescriber engaged in unprofessional conduct.